Benitec Biopharma (BNTC) Research & Development (2019 - 2025)

Benitec Biopharma has reported Research & Development for 7 years, with the latest figure at $5.8 million in Q4 2025.

• Quarterly Research & Development rose 8.34% year-over-year to $5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18.6 million (up 23.38% YoY) and the FY2025 annual result came in at $18.3 million, up 17.45% from the prior year.
• Research & Development grew to $5.8 million in Q4 2025 per BNTC's latest filing, from $3.4 million in the prior quarter.
• Over five years, Research & Development peaked at $6.5 million in Q1 2025 and troughed at $2.2 million in Q1 2022.
• A 5-year average of $3.6 million and a median of $3.2 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2021 and 2022: Research & Development soared 259.17% in 2021, then slipped 21.28% in 2022.
• Over 5 years, Research & Development stood at $3.1 million in 2021, then gained by 19.55% to $3.8 million in 2022, then jumped by 35.66% to $5.1 million in 2023, then advanced by 5.55% to $5.4 million in 2024, then increased by 8.34% to $5.8 million in 2025.
• According to Business Quant data, Research & Development over the past three periods registered $5.8 million, $3.4 million, and $2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.